• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Orexigen to be sold to Nalpropion Pharma for $75M

biospectrumasiaApril 25, 2018

Tag: Orexigen , Nalpropion Pharma

Orexigen, a California-based pharmaceutical company focused on development of treatments for obesity announced that it has inked an agreement with Nalpropion Pharmaceuticals to sell virtually all of its assets for $75M in cash.

Nalpropion is a newly formed special purpose entity capitalized by an investor group that includes Pernix Therapeutics. Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. 

The transaction is subject to higher/better offers.

Register as Visitor to CPhI China 2018!

Previous:Zymeworks, Celgene expand bispecific antibody partnership

Next:New leadership at Advaxis

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Orexigen to be sold to Nalpropion Pharma for $75M | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service